Obermatt
See Similar Stocks →

PolyNovo

ASX:PNV · AU000000PNV0
Health Care Equipment & SuppliesSmall

360

33
EV / EBIT6
Price / Owner Earnings97
Owner Earnings Yield1
Dividend Yield1
Price/Sales40
EV / Gross Profit46
Price/Book10
Return on Capital45
Cash Return on Capital27
Return on Equity79
EBIT Margin31
Gross Profitability98
Cash Conversion61
Accruals11
Owner Earnings Margin34
Sales growth72
Profit Growth28
Long-Term EPS Growth90
Owner Earnings Growth1
Reinvestment41
Price momentum31
Debt load60
Refinancing20
Debt Payback1
Liquidity46
Analyst ratings67
Opinion Changes50
Price Target Upside93
Market mood88
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

PolyNovo doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryAustralia
IndustryHealth Care Equipment & Supplies
SizeSmall
TypePublic Company
ExchangeASX
Founded1998
Websitepolynovo.com
ISINAU000000PNV0
Last UpdateApr 2, 2026
Indices
ASX 300 (Australia)
Themes
Biomedical EngineeringSurgeryOrthopaedicsMedical Device

Description

PolyNovo Limited, a biotechnology company, specializes in the development and commercialization of biomedical devices, primarily targeting the healthcare sector. The company is renowned for its innovative product offerings, particularly the Biodegrad…

Analysis

Middle-of-the-road

PolyNovo Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
42
2023202420252026

All-time high

42

Jun 2026

All-time low

1

Jan 2023

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
40
11
9
5
Price/Earnings
8
10
5
3
Price/Book
10
3
3
1
Dividend Yield
1
1
1
1
Value (overall)
10
7
6
3

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare PolyNovo with its peers
Zai Lab
HKG:9688
32
CountryChina
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dong-A ST
KSC:170900
39
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ansell
ASX:ANN
80
CountryAustralia
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Celltrion
KSC:068270
79
CountrySouth Korea
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Ascentage Pharma Group
HKG:6855
26
CountryChina
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Medical Developments International
ASX:MVP
79
CountryAustralia
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →